143540-05-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester is used as a key intermediate compound for the synthesis of LSD1 inhibitors. These inhibitors are important in the development of novel therapeutic strategies for various diseases, including cancer and neurological disorders. The compound's unique structure allows it to interact with the target enzyme, thereby modulating its activity and potentially leading to therapeutic benefits.
Used in Drug Development:
In the field of drug development, 2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester serves as a valuable building block for the creation of new molecules with potential biological activities. Its versatile chemical structure enables researchers to modify and optimize its properties, leading to the discovery of new drugs with improved efficacy, selectivity, and safety profiles.
Used in Chemical Research:
2-(Hydroxymethyl)-1,4-piperazinedicarboxylic acid 1,4-bis(tert-butyl) ester is also utilized in chemical research as a model compound for studying various reaction mechanisms and exploring new synthetic routes. Its unique functional groups and structural features make it an interesting subject for academic and industrial research, potentially leading to the development of innovative chemical processes and applications.

Upstream product

• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 543-27-1 isobutyl chloroformate 
• 13292-87-0 dimethyl sulfide borane 
• 171504-98-6 O₁,O₄-di-tert-butyl O₂-methyl piperazine-1,2,4-tricarboxylate 
• 28795-50-8 2-hydroxymethylpiperazine 

Downstream Products

• 935544-47-1 tert-butyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 1256815-07-2 di-tert-butyl 2-(aminomethyl)piperazine-1,4-dicarboxylate 
• 1246551-25-6 tert-butyl 3-oxo-1,2,5,6,8,8a-hexahydroimidazo[1,5-a]pyrazine-7-carboxylate 
• 1256815-19-6 hexahydro-2-(4-trifluoromethylphenyl)-imidazo[1,5-a]pyrazin-3-one 
• 1002404-84-3 2-benzylhexahydroimidazo[1,5-a]pyrazin-3(2H)-one 
• 1256815-98-1 tert-butyl 2-(4-(trifluoromethyl)phenyl)-hexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-88-9 tert-butyl 2-benzylhexahydro-3-oxoimidazo[1,5-a]pyrazine-7(1H)-carboxylate 
• 1256815-10-7 hexahydro-2-(4-fluorobenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1256815-11-8 hexahydro-2-(4-methylbenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1256815-12-9 hexahydro-2-(4-chlorobenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1256815-13-0 hexahydro-2-(4-methoxybenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1256815-17-4 hexahydro-2-(3-cyanobenzyl)-imidazo[1,5-a]pyrazin-3-one 
• 1256815-21-0 hexahydro-2-(4-fluorophenyl)-imidazo[1,5-a]pyrazin-3-one 
• 1002404-56-9 hexahydro-2-(4-chlorophenyl)-imidazo[1,5-a]pyrazin-3-one 

Relevant academic research and scientific papers

Application of piperazine structure containing compound to preparation of LSD1 (Lysine Specific Demethylase 1) inhibitor

The invention discloses application of a piperazine structure containing compound to the preparation of a histone lysine specific demethylase (LSD1) inhibitor. The structural general formula of the compound is as shown in the following descriptions (wherein, A is hydrogen, carbonyl or thiocarbonyl) or a configurational isomer and a pharmaceutical salt thereof, or is as shown in the following descriptions or a pharmaceutical salt thereof. The compound has an obvious inhibition effect on the LSD1, can be prepared into the LSD1 inhibitor, and is used for preventing and treating a disease related to the activity of the histone LSD1.

COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS

Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses as IDH1 mutants inhibitors for treating cancers are also provided

Tricyclic heterocyclic compound and use thereof

The present invention provides a tricyclic heterocyclic compound having a serotonin 5-HT2C receptor activation action and the like. A 5-HT2C receptor activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

An orthogonal protection strategy for the synthesis of 2-substituted piperazines

Tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-ones are readily prepared from the bis-carbamate protected piperazine-2-carboxylic acids and serve as orthogonally protected piperazines from which a variety of 2-substituted piperazines can be prepared. Sodium benzylate and sodium phenoxides react at the C-5 carbon of the oxazolidinone to yield 2-(benzyloxymethyl)piperazines and 2-(phenoxymethyl)piperazines, respectively. The tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-ones also provide convenient scaffolds from which 2-benzyl- and 2-phenethylpiperazines are prepared.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Pharmaceutical compounds

This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.

Xanthine derivatives as DPP-IV inhibitors

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, and R42 each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, which group may be substituted; and, R1 and R2 each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such, or salts or hydrates thereof.

CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.

CCR3 antagonist leads with IC(50) values in the microM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC(50) values for CCR3.